Agios Netherlands

Company snapshot

As an independent distributor and manufacturer of life science products and services for research and diagnostics, we strive to build long-term relationships with both our clients and suppliers. In accomplishing our mission, it is our experience that knowledge makes the difference. Sanbio is part of Europa Biosite, a European supplier of life science products and services. We are a group of six le

• 2 approved product(s) across US/EU regulatory metadata.
• 45 active pipeline program(s) linked via ClinicalTrials.gov.
• 93 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Agios Netherlands. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Agios Netherlands.

1. Jun 8, 2026 Clinical update

   Placebo Matching Mitapivat — Phase 3

2. Jun 8, 2026 Clinical update

   Mitapivat — Phase 3

3. Jun 8, 2026 Clinical update

   Mitapivat — Approved

4. Jun 8, 2026 Clinical update

   Mitapivat — Phase 3

5. Jun 8, 2026 Clinical update

   Mitapivat — Phase 3

View all clinical trial activity →

• What is Agios Netherlands?

  Agios Netherlands is a pharma organization headquartered in CAMBRIDGE, MA, NL. It trades on NYSE under ticker AGIO. Primary therapeutic focus areas include Pyruvate Kinase Deficiency, Sickle Cell Disease, Transfusion-dependent Alpha-Thalassemia, Anemia, Non-Transfusion-dependent

• Is Agios Netherlands publicly traded?

  Yes. Agios Netherlands is listed with ticker AGIO on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Agios Netherlands develop or market?

  We link 15 drug profile(s) where Agios Netherlands is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/agios-pharmaceuticals-inc#company-drugs.

• What are the latest developments for Agios Netherlands?

  In the last 12 months our linked public records show 45 trial program update(s) and 2 US patent grant(s) tied to this profile.

• What therapeutic areas does Agios Netherlands focus on?

  Agios Netherlands focuses on Pyruvate Kinase Deficiency, Sickle Cell Disease, Transfusion-dependent Alpha-Thalassemia based on our analysis of their pipeline programs and drug development activities.